Sylios Corp Retains Consultant to Expand Licensing Agreement

ST. PETERSBURG, FL / ACCESSWIRE / February 9, 2016 / Sylios Corp (OTC Pink: UNGS), a holding company with operations engaged in the exploration and development of oil and natural gas properties, site specific real estate development and holdings in equities, corporate debt and alternative investments is pleased to announce that it has retained the services of a Consultant to further expand on the sub-licensing and use of dispensary products.

The Company has retained the services of a Consultant to assist in the sub-licensing of the dispensary products granted to the Company in the licensing agreement entered into with Artemis Technologies. The Consultant will work through political avenues in an effort to broaden the scope of the use of the dispensary product and in an effort to license the use of the product in the States of Florida, Colorado and Washington.

The issue to legalize medical marijuana will appear on the Florida ballot to voters as 'Use of Marijuana for Debilitating Medical Conditions' and the text of the proposed constitutional amendment reads, in part, as follows:

(1) The medical use of marijuana by a qualifying patient or caregiver in compliance with this section is not subject to criminal or civil liability or sanctions under Florida law.

(2) A physician shall not be subject to criminal or civil liability or sanctions under Florida law solely for issuing a physician certification with reasonable care to a person diagnosed with a debilitating medical condition in compliance with this section.

(3) Actions and conduct by a Medical Marijuana Treatment Center registered with the Department, or its agents or employees, and in compliance with this section and Department regulations, shall not be subject to criminal or civil liability or sanctions under Florida law.

Under the ballot measure, patients would qualify to use medical marijuana if they suffered from AIDS, HIV, cancer, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, post-traumatic stress disorder, Crohn's disease, Parkinson's disease, "or other debilitating medical conditions of the same kind or class as or comparable to those enumerated, and for which a physician believes that the medical use of marijuana would likely outweigh the potential health risks for a patient." Medical marijuana dispensaries would be authorized as well.

Because it's a proposed state constitutional amendment, the ballot initiative will need 60 percent of the vote to pass. If it is successful, Florida will become the 24th state to legalize medical marijuana. Despite federal marijuana prohibition, measures such as this ballot initiative remain perfectly constitutional, and there is little if anything the feds can do to stop them in practice.

In addition to Florida, several key states will have the issue of medical and/or recreational marijuana on their state ballots in 2016. As additional states legalize the use of marijuana, the Consultant shall be granted additional territories.

About Sylios Corp

Sylios Corp, based in St. Petersburg, FL, is a holding corporation with operations engaged in the exploration and development of oil and natural gas properties, investments in equities and corporate debt and site specific real estate development.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein, and while expected, there is no guarantee that we will attain the aforementioned anticipated developmental milestones. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company. Additional risks and uncertainties are set forth in the Company's Unaudited Annual Report for the year ended December 31, 2014, which can be found on the OTC Markets website,


Sylios Corp
(727) 821-6200

SOURCE: Sylios Corp